Mayne Pharma Group Limited (MAYNF)
OTCMKTS
· Delayed Price · Currency is USD
3.085
0.00 (0.00%)
At close: Jun 3, 2025
Mayne Pharma Group Revenue
Mayne Pharma Group had revenue of 213.05M AUD in the half year ending December 31, 2024, with 307.91% growth. This brings the company's revenue in the last twelve months to 413.53M, up 64.47% year-over-year. In the fiscal year ending June 30, 2024, Mayne Pharma Group had annual revenue of 388.40M with 111.56% growth.
Revenue (ttm)
413.53M AUD
Revenue Growth
+64.47%
P/S Ratio
1.03
Revenue / Employee
427.64K AUD
Employees
967
Market Cap
264.69M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 388.40M | 204.81M | 111.56% |
Jun 30, 2023 | 183.59M | 26.44M | 16.82% |
Jun 30, 2022 | 157.15M | -243.63M | -60.79% |
Jun 30, 2021 | 400.78M | -56.20M | -12.30% |
Jun 30, 2020 | 456.99M | -68.22M | -12.99% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Mayne Pharma Group News
- 17 days ago - Why a private equity group is rethinking its bid for Mayne Pharma - The Australian Financial Review
- 17 days ago - Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal - Reuters
- 17 days ago - Mayne Pharma shares crash after suitor Cosette raises concerns - The Australian Financial Review
- 17 days ago - Mayne Pharma shares crash after suitor Cosette threatens to walk - The Australian Financial Review
- 17 days ago - ASX 200 LIVE: Mayne Pharma shares plunge; CBA hits record; JHX sales, earnings slip amid AZEK buy; ASIC sues Resimac, sharemarket rises - The Australian Financial Review
- 24 days ago - Disclosure doozy makes a mockery of Australia’s safe-haven fantasy - The Australian Financial Review
- 3 months ago - Mayne Pharma Group reports 1H results - Seeking Alpha
- 3 months ago - Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ... - GuruFocus